S
Symetis
Minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases
About Symetis
Symetis is a pioneering company in the medical technology sector, specializing in innovative solutions that enhance patient care. The company operates in the healthcare market, focusing on cardiovascular, gastroenterology, and urology specialties. Symetis serves a diverse range of clients, including hospitals, clinics, and medical professionals who require advanced medical devices to improve patient outcomes. The business model revolves around the development, manufacturing, and sale of high-quality medical devices such as single-use duodenoscopes, pacemakers, defibrillators, and stents. Revenue is generated through direct sales to healthcare providers and partnerships with medical institutions. Symetis is committed to sustainability and corporate social responsibility, ensuring that their operations positively impact communities worldwide.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2001
- Headquarters
- Ecublens, Switzerland
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 27.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Risk Management, Biotechnology, Cardiology and cardiovascular, Patient Care, Non-Invasive medical devices and treatments, Spinout, Arts & Culture, Digital Care, DT and LS, science-based
- Business model
- Manufacturing
- Investment activity
- 1 company, latest Feb 2017
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Dec 2024 | — | — | Biomed · Aravis Ventures · Novartis Venture Fund | — |
| ACQUISITIONOther financing | Apr 2017 | $435M | $435M | Boston Scientific | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Symetis is 0 monthly website visits, down 100% over the last three months. Symetis's team declined 4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Biomed
Series A6 investors entered at this stage
Aravis Ventures
Wellington Partners
Vinci Capital
Truffle Capital
Kreaxi
Novartis Venture Fund
Series B and later3 investors entered at this stage
NBGI Ventures
Endeavour Vision
Swisscom Ventures
Other known investors2 additional known investors
Boston Scientific
University of Zürich
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Symetis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Symetis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.